SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320: 2717.
  • 2
    Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 45965.
  • 3
    Presta L, Shields R, O'Connell L, Lahr S, Porter J, Gorman C, Jardieu P. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269: 2636873.
  • 4
    Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 262332.
  • 5
    Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della CG. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 25461.
  • 6
    Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 3028.
  • 7
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Gupta AA. Omalizumab, an anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 18490.
  • 8
    Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 30916.
  • 9
    Chanez P, Humbert M, Verkindre C, Tunon de Lara M, Molimard M. Diminution de l'expression des récepteurs FceRI dans l'asthme allergique persistant sévère traité par omalizumab. Rev Mal Respir 2009; 26 (Suppl. 1): S144.
  • 10
    Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function. J Allergy Clin Immunol 2004; 114: 52730.
  • 11
    Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004; 113: 297302.
  • 12
    MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, Kenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 143845.
  • 13
    Streck M, Tole J, Gandhi R, Loun T, Stewart C, Lew D. Omalizumab downregulates the expression of CD23 (FceRII) on human bronchial smooth muscle cells (HBSMC) in vitro. J Allergy Clin Immunol 2006; 117 (2 Suppl.): S9.
  • 14
    Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R, Holers VM, Hannan JP, Sutton BJ, Gould HJ, McDonnell JM. The structure of human CD23 and its interactions with IgE and CD21. J Exp Med 2005; 202: 75160.
  • 15
    Jung CM, Prinz JC, Rieber EP, Ring J. A reduction in allergen-induced Fc epsilon R2/CD23 expression on peripheral B cells correlates with successful hyposensitization in grass pollinosis. J Allergy Clin Immunol 1995; 95 (1 Pt 1): 7787.
  • 16
    Stämpfli MR, Miescher S, Aebischer I, Zurcher AW, Stadler BM. Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition. Eur J Immunol 1994; 24: 21617.
  • 17
    Davis FM, Gossett LA, Pinkston KL, Liou RS, Sun LK, Kim YW, Chang NT, Chang TW, Wagner K, Bews J. Can anti-IgE be used to treat allergy? Springer Semin Immunopathol 1993; 15: 5173.
  • 18
    Nopp A, Johansson SG, Ankerst J, Palmqvist M, Oman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007; 62: 117581.
  • 19
    Nopp A, Johansson SG, Adedoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65: 5660.
  • 20
    Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123: 10713.
  • 21
    Slavin RG, Jimenez P. Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma 2009; 46: 1023.
  • 22
    Katz RM, Rafi AW, Do L, Lin M, Mangat R, Azad N, Sender S. Efficacy of omalizumab using extended dose intervals. J Allergy Clin Immunol 2007; 119: s212.
  • 23
    Hanf G, Brachmann I, Kleine-Tebbe J, Seybold J, Kunkel G, Suttorp N, Noga O. Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. Allergy 2006; 61: 11414.
  • 24
    Steiss JO, Strohner P, Zimmer KP, Lindemann H. Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma 2008; 45: 2336.
  • 25
    Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 1828.
  • 26
    Lanier BQ. Unanswered questions and warnings involving anti-immunoglobulin E therapy based on 2-year observation of clinical experience. Allergy Asthma Proc 2005; 26: 4359.
  • 27
    Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63: 54861.
  • 28
    Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009; 68: 6176.
  • 29
    Meno-Tetang GM, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 2005; 96: 18292.
  • 30
    Long AA, Fish JE, Rahmaoui A, Miller MK, Bradley MS, Taki HN, Demeo AN, Tilles SA, Szefler SJ. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009; 103: 2129.
  • 31
    Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108: E36.
  • 32
    Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 1549.
  • 33
    Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della CG. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20: 738.
  • 34
    Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 6328.
  • 35
    Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124: 12106.
  • 36
    Riviere G-J, Keubler P, Jaffer J, Yeh C-M, Reynolds C, Brookman L. Novel omalizumab liquid formulation bioequivalent to lyophilized formulation. Eur Respir J 2008; 32 (Suppl. 52): 345s.
  • 37
    Florvaag E, Johansson SGO, Öman H, Harboe T, Nopp A. Pholcodine stimuates a dramatic increase of IgE in IgE-sensitized individuals. A pilot study. Allergy 2006; 61: 4955.
  • 38
    Waldmann TA, Iio A, Ogawa M, McIntyre OR, Strober W. The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. J Immunol 1976; 117: 113944.
  • 39
    Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol 2007; 93: 63119.
  • 40
    A Study Evaluating the Persistency of Response With or Without Xolair after Long-Term Therapy (XPORT). Study Start Date: May 2010. Available at http://clinicaltrials.gov/ct2/show/NCT01125748 (last accessed 11 April 2011).
  • 41
    Harboe T, Johansson SGO, Florvaag E, Öman H. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. Allergy 2007; 62: 144550.
  • 42
    Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101: 148392.